WeVote
Log In

Bill

Bill

HB 1399

RELATING TO OPIOID ANTAGONISTS.

2026 Regular Session Introduced by David Alcos and 3 co-sponsors

HB 1399 establishes opioid antagonist provisions in Hawaii, likely expanding access to naloxone and overdose reversal medications to reduce opioid-related deaths.

Carried over to 2026 Regular Session.
#appropriation($) #classrooms #doe #opioidantagonist
0
WeVote Research Nonpartisan
Bill Summary · HB 1399

Legislative bill overview

HB 1399 relates to opioid antagonists (medications like naloxone/Narcan that reverse opioid overdoses) in Hawaii, though the specific provisions are not detailed in the available information. The bill was introduced in January 2025 and has been referred to Education, Health, and Finance committees for review.

Why is this important

Opioid antagonist legislation typically addresses access, distribution, and use of life-saving overdose reversal medications. Hawaii, like most states, faces ongoing opioid-related deaths and emergency situations where rapid access to naloxone can prevent fatalities. Policy in this area directly affects public health outcomes and emergency response capabilities.

Potential points of contention

  • Access and distribution scope — Whether antagonists should be widely available over-the-counter, in schools, at public venues, or restricted to medical settings; this affects implementation costs and public health philosophy
  • Liability and legal protections — Whether providers, businesses, and bystanders administering opioid antagonists receive legal immunity, which influences willingness to stock and use these medications
  • Funding mechanisms — How the state will pay for expanded access, distribution programs, and training; referred to Finance committee suggests cost concerns exist

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.